journal article·2024-08-14Open access

Nanomaterials in Immunology: Bridging Innovative Approaches in Immune Modulation, Diagnostics, and Therapy

George-Alexandru Croitoru, Diana-Cristina Pîrvulescu, Adelina-Gabriela Niculescu, Dragoș Epistatu, Marius Rădulescu, Alexandru Mihai Grumezescu, Carmen-Larisa Nicolae

Abstract

The intersection of immunology and nanotechnology has provided significant advancements in biomedical research and clinical applications over the years. Immunology aims to understand the immune system’s defense mechanisms against pathogens. Nanotechnology has demonstrated its potential to manipulate immune responses, as nanomaterials’ properties can be modified for the desired application. Research has shown that nanomaterials can be applied in diagnostics, therapy, and vaccine development. In diagnostics, nanomaterials can be used for biosensor development, accurately detecting biomarkers even at very low concentrations. Therapeutically, nanomaterials can act as efficient carriers for delivering drugs, antigens, or genetic material directly to targeted cells or tissues. This targeted delivery improves therapeutic efficacy and reduces the adverse effects on healthy cells and tissues. In vaccine development, nanoparticles can improve vaccine durability and extend immune responses by effectively delivering adjuvants and antigens to immune cells. Despite these advancements, challenges regarding the safety, biocompatibility, and scalability of nanomaterials for clinical applications are still present. This review will cover the fundamental interactions between nanomaterials and the immune system, their potential applications in immunology, and their safety and biocompatibility concerns.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania

Faculty of Chemical Engineering and Biotechnology, National University of Science and Technology Politehnica Bucharest, 011061 Bucharest, Romania

Research Institute of the University of Bucharest—ICUB, University of Bucharest, 050657 Bucharest, Romania

References (100+)

Show source-provided references
1. An introduction to immunology and immunopathology10.1186/s13223-018-0278-1 ↗
2. Key concepts in immunology10.1016/j.vaccine.2010.07.022 ↗
3. The science and medicine of human immunology10.1126/science.aay4014 ↗
4. Principles and therapeutic applications of adaptive immunity10.1016/j.cell.2024.03.037 ↗
5. The Role of Nanomaterials in the Treatment of Diseases and Their Effects on the Immune System10.3889/oamjms.2019.486 ↗
6. The first line of defence: Insights into mechanisms and relevance of phagocytosis in epithelial cells10.1007/s00281-018-0701-1 ↗
7. McDonald, D.R., and Levy, O. (2019). Innate immunity. Clinical Immunology, Elsevier.10.1016/B978-0-7020-6896-6.00003-X ↗
8. Pal, A., and Chakravarty, A.K. (2020). Chapter 4-Basic concepts of immunogenetics. Genetics and Breeding for Disease Resistance of Livestock, Academic Press.10.1016/B978-0-12-816406-8.00004-8 ↗
9. Applications of nanotechnology for immunology10.1038/nri3488 ↗
10. Mobeen, H., Safdar, M., Fatima, A., Afzal, S., Zaman, H., and Mehdi, Z. (2022). Emerging applications of nanotechnology in context to immunology: A comprehensive review. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.1024871 ↗
11. Biomedical nanomaterials for immunological applications: Ongoing research and clinical trials10.1039/D0NA00478B ↗
12. Mabrouk, M., Das, D.B., Salem, Z.A., and Beherei, H.H. (2021). Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. Molecules, 26.10.3390/molecules26041077 ↗
13. Pandey, S. (2022). Advance Nanomaterials for Biosensors. Biosensors, 12.10.3390/books978-3-0365-4326-0 ↗
14. Hou, S., Zhang, A., and Su, M. (2016). Nanomaterials for Biosensing Applications. Nanomaterials, 6.10.3390/nano6040058 ↗
15. Mitarotonda, R., Giorgi, E., Eufrasio-da-Silva, T., Dolatshahi-Pirouz, A., Mishra, Y.K., Khademhosseini, A., Desimone, M.F., De Marzi, M., and Orive, G. (2022). Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines. Biomater. Adv., 135.10.1016/j.bioadv.2022.212726 ↗
16. Nanomaterials for cancer therapy: Current progress and perspectives10.1186/s13045-021-01096-0 ↗
17. Luzuriaga, M.A., Shahrivarkevishahi, A., Herbert, F.C., Wijesundara, Y.H., and Gassensmith, J.J. (2021). Biomaterials and nanomaterials for sustained release vaccine delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology, 13.10.1002/wnan.1735 ↗
18. Aljabali, A.A., Obeid, M.A., Bashatwah, R.M., Serrano-Aroca, Á., Mishra, V., Mishra, Y., El-Tanani, M., Hromić-Jahjefendić, A., Kapoor, D.N., and Goyal, R. (2023). Nanomaterials and Their Impact on the Immune System. Int. J. Mol. Sci., 24.10.3390/ijms24032008 ↗
19. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats10.2217/17435889.3.5.703 ↗
20. Size-dependent in vivo transport of nanoparticles: Implications for delivery, targeting, and clearance10.1021/acsnano.3c05853 ↗
21. Fadeel, B. (2019). Hide and Seek: Nanomaterial Interactions With the Immune System. Front. Immunol., 10.10.3389/fimmu.2019.00133 ↗
22. Nanoparticle protein corona: From structure and function to therapeutic targeting10.1039/D2LC00799A ↗
23. Niculescu, A.-G., Bîrcă, A.C., and Grumezescu, A.M. (2021). New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery. Pharmaceutics, 13.10.3390/pharmaceutics13122053 ↗
24. Moraru, C., Mincea, M., Menghiu, G., and Ostafe, V. (2020). Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications. Molecules, 25.10.3390/molecules25204758 ↗
25. La-Beck, N.M., and Gabizon, A.A. (2017). Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Front. Immunol., 8.10.3389/fimmu.2017.00416 ↗
26. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption10.1016/S0927-7765(99)00156-3 ↗
27. Nasrullah, M., Meenakshi Sundaram, D.N., Claerhout, J., Ha, K., Demirkaya, E., and Uludag, H. (2023). Nanoparticles and cytokine response. Front. Bioeng. Biotechnol., 11.10.3389/fbioe.2023.1243651 ↗
28. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy10.1002/adma.202313226 ↗
29. Benne, N., Ter Braake, D., Stoppelenburg, A.J., and Broere, F. (2022). Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases. Front. Immunol., 13.10.3389/fimmu.2022.864403 ↗
30. Kishimoto, T.K., and Maldonado, R.A. (2018). Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance. Front. Immunol., 9.10.3389/fimmu.2018.00230 ↗
31. Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy10.1016/j.biomaterials.2016.03.039 ↗
32. Pathogen-mimicking polymeric nanoparticles based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses10.1002/smll.201503662 ↗
33. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants10.1016/j.biomaterials.2011.05.063 ↗
34. Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery10.1021/acsnano.0c03109 ↗
35. Immunosuppressive and anti-inflammatory properties of engineered nanomaterials10.1111/bph.12722 ↗
36. Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver10.1021/acsnano.1c02391 ↗
37. Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy10.7150/thno.37216 ↗
38. Crossing the blood-brain barrier with nanoparticles10.1016/j.jconrel.2017.12.015 ↗
39. Zhong, G., Long, H., Zhou, T., Liu, Y., Zhao, J., Han, J., Yang, X., Yu, Y., Chen, F., and Shi, S. (2022). Blood-brain barrier Permeable nanoparticles for Alzheimer’s disease treatment by selective mitophagy of microglia. Biomaterials, 288.10.1016/j.biomaterials.2022.121690 ↗
40. Lu, L., Qi, S., Chen, Y., Luo, H., Huang, S., Yu, X., Luo, Q., and Zhang, Z. (2020). Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials, 245.10.1016/j.biomaterials.2020.119987 ↗
41. Molecular and immunological toxic effects of nanoparticles10.1016/j.ijbiomac.2017.09.110 ↗
42. Role of Nanomaterials in COVID-19 Prevention, Diagnostics, Therapeutics, and Vaccine Development10.3390/jnt3040011 ↗
43. Colorimetric detection of DNA, small molecules, proteins, and ions using unmodified gold nanoparticles and conjugated polyelectrolytes10.1073/pnas.1005632107 ↗
44. Peng, Y., Pan, Y., Sun, Z., Li, J., Yi, Y., Yang, J., and Li, G. (2021). An electrochemical biosensor for sensitive analysis of the SARS-CoV-2 RNA. Biosens. Bioelectron., 186.10.1016/j.bios.2021.113309 ↗
45. An ultrasensitive label-free electrochemical immunosensor based on 3D porous chitosan–graphene–ionic liquid–ferrocene nanocomposite cryogel decorated with gold nanoparticles for prostate-specific antigen10.1016/j.talanta.2020.121787 ↗
46. Oh, H.-K., Kim, K., Park, J., Im, H., Maher, S., and Kim, M.-G. (2022). Plasmon color-preserved gold nanoparticle clusters for high sensitivity detection of SARS-CoV-2 based on lateral flow immunoassay. Biosens. Bioelectron., 205.10.1016/j.bios.2022.114094 ↗
47. Development of polypyrrole (nano)structures decorated with gold nanoparticles toward immunosensing for COVID-19 serological diagnosis10.1016/j.mtchem.2022.100817 ↗
48. Label-free electrochemical immunosensor for the detection of prostate specific antigen based three-dimensional Au nanoparticles/MoS2-graphene aerogels composite10.1016/j.inoche.2020.108122 ↗
49. A novel label-free impedimetric immunosensor for sensitive detection of prostate specific antigen using Au nanoparticles/MWCNTs- graphene quantum dots nanocomposite10.1016/j.microc.2020.105301 ↗
50. A sandwich ELISA-like detection of C-reactive protein in blood by citicoline-bovine serum albumin conjugate and aptamer-functionalized gold nanoparticles nanozyme10.1016/j.talanta.2020.121070 ↗
51. Hepel, M. (2020). Magnetic Nanoparticles for Nanomedicine. Magnetochemistry, 6.10.3390/magnetochemistry6010003 ↗
52. Bhandari, D., Chen, F.-C., and Bridgman, R.C. (2022). Magnetic Nanoparticles Enhanced Surface Plasmon Resonance Biosensor for Rapid Detection of Salmonella Typhimurium in Romaine Lettuce. Sensors, 22.10.3390/s22020475 ↗
53. Fast and sensitive immuno-PCR assisted by plasmonic magnetic nanoparticles10.1016/j.apmt.2021.101054 ↗
54. Visualization of vaccine dynamics with quantum dots for immunotherapy10.1002/ange.202111093 ↗
55. Liu, F., Sun, J., Yu, W., Jiang, Q., Pan, M., Xu, Z., Mo, F., and Liu, X. (2020). Quantum dot-pulsed dendritic cell vaccines plus macrophage polarization for amplified cancer immunotherapy. Biomaterials, 242.10.1016/j.biomaterials.2020.119928 ↗
56. Nanoparticles and Vaccine Development10.2174/2211738507666191024162042 ↗
57. Lozano, D., Larraga, V., Vallet-Regí, M., and Manzano, M. (2023). An Overview of the Use of Nanoparticles in Vaccine Development. Nanomedicine, 13.10.3390/nano13121828 ↗
58. Curley, S.M., and Putnam, D. (2022). Biological Nanoparticles in Vaccine Development. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.867119 ↗
59. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics10.1038/s12276-023-01086-x ↗
60. Lipid nanoparticles in the development of mRNA vaccines for COVID-1910.1016/j.jddst.2022.103553 ↗
61. Shimosakai, R., Khalil, I.A., Kimura, S., and Harashima, H. (2022). mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines. Pharmaceuticals, 15.10.3390/ph15081017 ↗
62. Sasaki, K., Sato, Y., Okuda, K., Iwakawa, K., and Harashima, H. (2022). mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy. Pharmaceutics, 14.10.3390/pharmaceutics14081572 ↗
63. Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response10.1073/pnas.2207841119 ↗
64. Henson, T.R., Richards, K.A., Gandhapudi, S.K., Woodward, J.G., and Sant, A.J. (2023). R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination. Viruses, 15.10.3390/v15020538 ↗
65. Nguyen, T.N., Kumari, S., Sillman, S., Chaudhari, J., Lai, D.C., and Vu, H.L.X. (2023). A Single-Dose Intramuscular Immunization of Pigs with Lipid Nanoparticle DNA Vaccines Based on the Hemagglutinin Antigen Confers Complete Protection against Challenge Infection with the Homologous Influenza Virus Strain. Vaccines, 11.10.1101/2023.08.22.554288 ↗
66. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease10.1016/j.ymthe.2023.07.022 ↗
67. mRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids10.1002/adfm.202204692 ↗
68. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus10.1038/s41392-023-01432-5 ↗
69. Gill, H.S., and Compans, R.W. (2021). Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles. Nanoparticles for Rational Vaccine Design, Springer International Publishing.10.1007/978-3-030-85067-8 ↗
70. Wibowo, D., Jorritsma, S.H.T., Gonzaga, Z.J., Evert, B., Chen, S., and Rehm, B.H.A. (2021). Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials, 268.10.1016/j.biomaterials.2020.120597 ↗
71. Niculescu, A.-G., and Grumezescu, A.M. (2021). Polymer-Based Nanosystems—A Versatile Delivery Approach. Materials, 14.10.3390/ma14226812 ↗
72. Amin, M.K., and Boateng, J. (2023). Surface functionalization of PLGA nanoparticles for potential oral vaccine delivery targeting intestinal immune cells. Colloids Surf. B Biointerfaces, 222.10.1016/j.colsurfb.2022.113121 ↗
73. A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against Acinetobacter baumannii Infection10.2147/IJN.S296527 ↗
74. Enhanced immunogenicity of foot and mouth disease DNA vaccine delivered by PLGA nanoparticles combined with cytokine adjuvants10.1016/j.rvsc.2021.02.010 ↗
75. Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice10.1016/j.ijbiomac.2020.02.287 ↗
76. Cheng, X., Xie, Q., and Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. Front. Bioeng. Biotechnol., 11.10.3389/fbioe.2023.1177151 ↗
77. Egwu, C.O., Aloke, C., Onwe, K.T., Umoke, C.I., Nwafor, J., Eyo, R.A., Chukwu, J.A., Ufebe, G.O., Ladokun, J., and Audu, D.T. (2024). Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules, 29.10.3390/molecules29112584 ↗
78. Toxicology and clinical potential of nanoparticles10.1016/j.nantod.2011.10.001 ↗
79. Nanoparticle delivery of cardioprotective therapies
80. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum10.3390/pharmaceutics7040438 ↗
81. Yang, C., Yang, J., Lu, A., Gong, J., Yang, Y., Lin, X., Li, M., and Xu, H. (2022). Nanoparticles in ocular applications and their potential toxicity. Front. Mol. Biosci., 9.10.3389/fmolb.2022.931759 ↗
82. Recent advances in nanotechnology for Intra-nasal drug delivery and clinical applications10.1016/j.jddst.2023.104726 ↗
83. Khatun, S., Putta, C.L., Hak, A., and Rengan, A.K. (2023). Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Biomater. Biosyst., 9.10.1016/j.bbiosy.2023.100073 ↗
84. El-Deeb, N.M., Abo-Eleneen, M.A., Al-Madboly, L.A., Sharaf, M.M., Othman, S.S., Ibrahim, O.M., and Mubarak, M.S. (2020). Biogenically Synthesized Polysaccharides-Capped Silver Nanoparticles: Immunomodulatory and Antibacterial Potentialities Against Resistant Pseudomonas aeruginosa. Front. Bioeng. Biotechnol., 8.10.3389/fbioe.2020.00643 ↗
85. Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis10.1016/j.ijpharm.2021.120935 ↗
86. MicroRNA-125a-Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Restoring Effector/Regulatory T Cells Balance10.1021/acsnano.9b09998 ↗
87. Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice10.1080/21645515.2021.1872342 ↗
88. Nanotechnology in cancer therapy10.3109/1061186X.2013.837469 ↗
89. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
90. The tumor microenvironment10.1016/j.cub.2020.06.081 ↗
91. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine10.1016/j.semcancer.2022.03.026 ↗
92. Nanotechnology-based products for cancer immunotherapy10.1007/s11033-021-06876-y ↗
93. Improving cancer immunotherapy through nanotechnology10.1038/s41568-019-0186-9 ↗
94. Cavalcanti, I.D.L., and Soares, J.C.S. (2021). Conventional Chemotherapy Versus Targeted Therapy. Advances in Cancer Treatment: From Systemic Chemotherapy to Targeted Therapy, Springer International Publishing.10.1007/978-3-030-68334-4 ↗
95. Targeted cancer therapy--are the days of systemic chemotherapy numbered?10.1016/j.maturitas.2013.09.008 ↗
96. Nanotherapeutics to overcome conventional cancer chemotherapy limitations10.18433/J30C7D ↗
97. Yu, X., Fang, C., Zhang, K., and Su, C. (2022). Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment. Pharmaceutics, 14.10.3390/pharmaceutics14081581 ↗
98. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy10.1038/s41401-022-00910-w ↗
99. Kiaie, S.H., Salehi-Shadkami, H., Sanaei, M.J., Azizi, M., Shokrollahi Barough, M., Nasr, M.S., and Sheibani, M. (2023). Nano-immunotherapy: Overcoming delivery challenge of immune checkpoint therapy. J. Nanobiotechnology, 21.10.1186/s12951-023-02083-y ↗
100. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy10.1038/s41467-021-27434-x ↗